Methods: All patients included in the original study were followed clinically for a period of up to 6 months after discontinuation of antiviral treatment.
Results: The study population consisted of 110 solid organ and allogeneic hematopoietic stem cell transplant recipients with a total of 125 episodes of CMV disease. There was no significant difference in median age, gender, type of transplant and type of CMV disease between the WHO-CA group and the LDT group. At 6 months, CMV relapse was observed in 25% of all patients, including 14/64 (22%) CMV episodes monitored by WHO-CA compared to 17/61 (28%) of CMV episodes monitored by LDT; the difference was not statistically significant (p=0.232).
Conclusion: Current guidelines recommend that antiviral treatment be continued until two weekly negative CMV QNAT (which is at least 14 days of negative viral load in the blood). This study challenges this approach, since the rate of CMV relapse did not increase significantly despite a duration shorter than the recommended 14 days after viremia eradication; this could therefore translate to improved cost savings and less toxicity. However, the rate of CMV relapse remains notably high, and analysis of factors predisposing to CMV relapse should be performed.
R. R. Razonable, None
See more of: Poster Abstract Session